Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Yousif Matloub, MD, Lia Gore, MD, Mignon L. Loh, MD, Chin-Hon Pui, MD, Michael J. Hanley, PharmD, PhD, Vickie Lu, PhD, E. Jane Leonard, MSc, Muriel Granier, Andrea Biondi, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-134724

Published: 2020

Journal Articles

Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Children's Hospitals

Ajay Gupta, MD, Yousif Matloub, MD, Rahul Damania, MD, MaryAnn O'Riordan, Sanjay P Ahuja, MD

Blood (2017) 130 (Supplement 1): 222.

https://doi.org/10.1182/blood.V130.Suppl_1.222.222

Published: 2017

Journal Articles

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Leonard A. Mattano, MD, Meenakshi Devidas, PhD, Alison M. Friedmann, MD MSC, Elizabeth A. Raetz, MD, Mignon Loh, MD, Patrick Buckley, MD PhD, Michael J. Borowitz, MD PhD, Andrew J. Carroll, PhD, Julie Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan-Lottick, MD MSPH, Yousif Matloub, MD, David T Marshall, MD, Linda C. Stork, MD, Brent L. Wood, MD PhD, Naomi J. Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Kelly Maloney, MD

Blood (2014) 124 (21): 793.

https://doi.org/10.1182/blood.V124.21.793.793

Published: 2014

Journal Articles

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Kelly W. Maloney, MD, Meenakshi Devidas, PhD, Leonard A. Mattano, Jr., MD, Alison M. Friedmann, MD, MSC, Patrick Buckley, MD, PhD, Michael J. Borowitz, MD, PhD, Andrew J. Carroll, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan -lottick, Mignon L. Loh, MD, Yousif Matloub, MD, David T. Marshall, MD, Linda C. Stork, MD, Elizabeth A. Raetz, MD, Brent L. Wood, MD, PhD, Naomi J. Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2013) 122 (21): 837.

https://doi.org/10.1182/blood.V122.21.837.837

Published: 2013

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Yousif Matloub, MD, Bruce C. Bostrom, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Stephen P Hunger, MD, Harland Sather, PhD, Stephen Linda, William L. Carroll, MD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2009) 114 (22): 320.

https://doi.org/10.1182/blood.V114.22.320.320

Published: 2009

Journal Articles

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Hanna Jean Khoury, MD, Michael J. Mauro, MD, Yousif Matloub, MD, Tai-Tsang Chen, PhD, Erkut Bahceci, MD, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 1128.

https://doi.org/10.1182/blood.V114.22.1128.1128

Published: 2009

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Paul S. Gaynon, MD, Bruce C. Camitta, MD, Yousif Matloub, MD, Paul L. Martin, MD, Naomi Winick, MD, Nita L. Seibel, MD, W. Paul Bowman, MD, Harland N. Sather, PhD, Meenakshi Devidas, PhD, Stephen Hunger, MD, William L. Carroll, MD

Blood (2007) 110 (11): 847.

https://doi.org/10.1182/blood.V110.11.847.847

Published: 2007

Journal Articles

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Yousif Matloub, MD, Anne Angiolillo, MD, Bruce Bostrom, MD, Stephen P. Hunger, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Naomi Winick, MD, Paul S. Gaynon, MD

Blood (2006) 108 (11): 146.

https://doi.org/10.1182/blood.V108.11.146.146

Published: 2006

Journal Articles

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Robert C. Trueworthy, MD, Linda Stork, MD, Yanping Zhong, MD, Sharon Pine, PhD, Yousif Matloub, MD, Ted Laderas, MS, Shannon McWeeney, PhD, Guang Fan, MD, PhD

Blood (2006) 108 (11): 1834.

https://doi.org/10.1182/blood.V108.11.1834.1834

Published: 2006

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

NARROW

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Children's Hospitals

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only